HDAC9 and cancer: The preservation of HDAC1, HDAC2, and HDAC5 expression suggests that BKS-112 may offer reduced toxicity compared to pan-HDAC inhibitors while maintaining potent anticancer activity through coordinated inhibition of HDAC6, HDAC3, and HDAC4, which are critically involved in cancer cell survival, proliferation, and metastasis.